reports
Heineken Holding N.V. reports transactions under its current share buy...
Heineken Holding N.V. reports transactions under its current share buyback programme Heineken Holding N.V. reports transactions under its current share buyback programme Amsterdam, 28 April 2026 - Heineken Holding N.V. (EURONEXT:HEIO; OTCQX: HKHHY), hereby reports transaction details related to the second tranche of up to circa €375 million tranche of its share buyback programme of up to circa €750 million as communicated on 12 February 2026. From 20 April 2026 up to and including 24 April 2026 a total of 68,012 shares were repurchased on exchange at an average price of € 61.90. Up t...
- Delphine Brault
- Nathan Mietlicki
GALP GALP ENERGIA SGPS SA CLASS B
DB1 DEUTSCHE BOERSE AG
SSAB A SSAB AB CLASS A
NOVN NOVARTIS AG
ITRK INTERTEK GROUP PLC
SAN SANOFI
ASSA B ASSA ABLOY AB CLASS B
STR STRABAG SE
BP. BP P.L.C.
STM STMICROELECTRONICS NV
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
CCEP COCA-COLA EUROPEAN PARTNERS PLC
SIGN SIG COMBIBLOC GROUP LTD
SHEL SHELL PLC
AAL ANGLO AMERICAN PLC
- Delphine Brault
- Nathan Mietlicki
GALP GALP ENERGIA SGPS SA CLASS B
DB1 DEUTSCHE BOERSE AG
SSAB A SSAB AB CLASS A
NOVN NOVARTIS AG
ITRK INTERTEK GROUP PLC
SAN SANOFI
ASSA B ASSA ABLOY AB CLASS B
STR STRABAG SE
BP. BP P.L.C.
STM STMICROELECTRONICS NV
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
CCEP COCA-COLA EUROPEAN PARTNERS PLC
SIGN SIG COMBIBLOC GROUP LTD
SHEL SHELL PLC
AAL ANGLO AMERICAN PLC
- Florent Cespedes
- Martial Descoutures
- Florent Cespedes
- Martial Descoutures
Press Release: Sanofi successfully prices 2.3 billion of bond issue
Press Release: Sanofi successfully prices 2.3 billion of bond issue Sanofi successfully prices 2.3 billion of bond issue Paris, April 24, 2026 - Sanofi announces that it has successfully priced its offering of €2.3 billion of notes across 3 tranches: €1,000 million fixed-rate notes, due May 2029, bearing interest at an annual rate of 3.000% €650 million fixed-rate notes, due May 2033, bearing interest at an annual rate of 3.375% €650 million fixed-rate notes, due May 2037, bearing interest at an annual rate of 3.750% The notes are being issued under Sanofi's Euro Medium Term Note pro...
Communiqué de presse : Sanofi place 2,3 milliard d’euros d’emprunts ob...
Communiqué de presse : Sanofi place 2,3 milliard d’euros d’emprunts obligataires Sanofi place 2,3 milliard d’euros d’emprunts obligataires Paris, 24 avril 2026 - Sanofi annonce avoir placé avec succès une émission obligataire en 3 tranches (les « obligations ») pour un montant de 2,3 milliards d’euros : 1 000 millions d’euros d’obligations à taux fixe, échéance mai 2029, portant intérêt au taux annuel de 3,000% 650 millions d’euros d’obligations à taux fixe, échéance mai 2033, portant intérêt au taux annuel de 3,375% 650 millions d’euros d’obligations à taux fixe, échéance mai 2037, por...
Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU app...
Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses Recommendation based on the HERCULES phase 3 study which demonstrated that brain-penetrant Cenrifki (tolebrutinib) significantly delayed the onset of disability progression in non-relapsing SPMS Paris, April 24, 2026. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CH...
Communiqué de presse : Cenrifki de Sanofi (tolebrutinib) recommandé pa...
Communiqué de presse : Cenrifki de Sanofi (tolebrutinib) recommandé par le Comité des médicaments à usage humain (CMUH) pour être approuvé par l’UE pour le traitement de la sclérose en plaques secondairement progressive sans poussées Cenrifki de Sanofi (tolebrutinib) recommandé par le Comité des médicaments à usage humain (CMUH) pour être approuvé par l’UE pour le traitement de la sclérose en plaques secondairement progressive sans poussées Recommandation basée sur HERCULES, une étude de phase 3 qui a démontré que Cenrifki (tolebrutinib) pénétrant dans le cerveau retardait significativemen...
HEINEKEN HOLDING N.V. ANNUAL GENERAL MEETING ADOPTS ALL PROPOSALS
HEINEKEN HOLDING N.V. ANNUAL GENERAL MEETING ADOPTS ALL PROPOSALS Amsterdam, 23 April 2026 HEINEKEN HOLDING N.V. ANNUAL GENERAL MEETING ADOPTS ALL PROPOSALS Heineken Holding N.V. announced today that its Annual General Meeting of Shareholders (AGM) has adopted all proposals on the agenda of the AGM. The key resolutions are listed below. DividendThe Board of Directors announced the distribution of a dividend for the year 2025 of EUR 1.90 per share. As an interim dividend of EUR 0.74 was paid on 7 August 2025, the final dividend of EUR 1.16 per share will be made payable on 5 May 2026. H...
- Maissa Keskes
- Stephane Houri
HEIA HEINEKEN NV
GET GETLINK SE
EDEN EDENRED SA
IPN IPSEN SA
CA CARREFOUR SA
BVI BUREAU VERITAS SA
BN DANONE SA
BNP BNP PARIBAS SA CLASS A
RNO RENAULT SA
ORA ORANGE SA
CBK COMMERZBANK AG
GFC GECINA SA
ABB ABB LTD.
SAND SANDVIK AB
RXL REXEL SA
LSEG LONDON STOCK EXCHANGE GROUP PLC
SRT3 SARTORIUS AG PREF
NOKIA NOKIA OYJ
EL ESSILORLUXOTTICA SA
NESN NESTLE S.A.
OR L'OREAL SA
SCHP SCHINDLER HOLDING AG PREF
SAN SANOFI
SAF SAFRAN S.A.
MOCORP METSO OUTOTEC OYJ
DIM SARTORIUS STEDIM BIOTECH SA
BIM BIOMERIEUX SA
BG BAWAG GROUP AG
STM STMICROELECTRONICS NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
DSY DASSAULT SYSTEMES SA
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
SGSN SGS SA
GALD GALDERMA GROUP AG
ROG ROCHE HOLDING AG
- Maissa Keskes
- Stephane Houri
HEIA HEINEKEN NV
GET GETLINK SE
EDEN EDENRED SA
IPN IPSEN SA
CA CARREFOUR SA
BVI BUREAU VERITAS SA
BN DANONE SA
BNP BNP PARIBAS SA CLASS A
RNO RENAULT SA
ORA ORANGE SA
CBK COMMERZBANK AG
GFC GECINA SA
ABB ABB LTD.
SAND SANDVIK AB
RXL REXEL SA
LSEG LONDON STOCK EXCHANGE GROUP PLC
SRT3 SARTORIUS AG PREF
NOKIA NOKIA OYJ
EL ESSILORLUXOTTICA SA
NESN NESTLE S.A.
OR L'OREAL SA
SCHP SCHINDLER HOLDING AG PREF
SAN SANOFI
SAF SAFRAN S.A.
MOCORP METSO OUTOTEC OYJ
DIM SARTORIUS STEDIM BIOTECH SA
BIM BIOMERIEUX SA
BG BAWAG GROUP AG
STM STMICROELECTRONICS NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
DSY DASSAULT SYSTEMES SA
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
SGSN SGS SA
GALD GALDERMA GROUP AG
ROG ROCHE HOLDING AG
- Florent Cespedes
- Martial Descoutures
- Florent Cespedes
- Martial Descoutures
- Rafael Bonardell
- Research Department
INFORME DIARIO 23 ABRIL + RDOS. ESPAÑA Y EUROPA 1T’26. IDEAS DESTACADA...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: BANKINTER, REPSOL, SECTOR INMOBILIARIO, TELEFÓNICA. EUROPA: ESSILORLUXOTTICA, L’OREAL, NOKIA, SAFRAN, SANOFI Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 1T’26 que se publicarán en España y Europa en los próximos días. Un mercado con mucha incertidumbre A pesar de la prórroga del alto al fuego las bolsas ...
Press Release: Q1 2026: double-digit sales and business EPS growth
Press Release: Q1 2026: double-digit sales and business EPS growth Q1 2026: double-digit sales and business EPS growth Paris, April 23, 2026 Q1 sales growth of 13.6% at CER1 and business earnings per share (EPS)2 of €1.88 Pharma launches sales increased by 49.6%, reaching €1.2 billion, driven primarily by Ayvakit, ALTUVIIIO, and SarclisaDupixent sales increased by 30.8% to €4.2 billion, a strong start to 2026Vaccines sales increased by 2.1% to €1.3 billion, benefiting from Heplisav-BResearch and Development expenses reached €1.7 billion, up by 1.5%Selling and general expenses reached €2....
Communiqué de presse : T1 2026 : croissance à deux chiffres du chiffre...
Communiqué de presse : T1 2026 : croissance à deux chiffres du chiffre d’affaires et du BNPA T1 2026 : croissance à deux chiffres du chiffre d’affaires et du BNPA Paris, le 23 avril 2026 Ventes du T1 en progression de 13,6 % à TCC1 et BNPA2 des activités de 1,88 euro Les ventes des nouveaux lancements Pharma progressent de 49,6 %, atteignant 1,2 milliard d’euros, principalement portées par Ayvakit, ALTUVIIIO et SarclisaLes ventes de Dupixent progressent de 30,8 %, à 4,2 milliards d’euros, marquant un fort démarrage en 2026Les ventes de Vaccins augmentent de 2,1 %, à 1,3 milliard d’...
HEINEKEN HOLDING N.V. 2026 FIRST QUARTER TRADING UPDATE
HEINEKEN HOLDING N.V. 2026 FIRST QUARTER TRADING UPDATE Amsterdam, 23 April 2026 HEINEKEN HOLDING N.V. 2026 FIRST QUARTER TRADING UPDATE Solid first quarter with quality volume growth IFRS Measures BEIA Measures(in € million) Totalgrowth (in € million) Organic growthTotal volume 66.4 2.8 % Total volume 66.4 1.2 %Revenue 7,892 1.4 % Revenue (beia) 7,888 2.2 %Net revenue 6,703 2.5 % Net revenue (beia) 6,699 2.8 % Heineken Holding N.V. engages in no activities other than its participating interest in Heineken N.V. and the...
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as t...
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria Approval for children aged two to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical study programCSU is a chronic skin disease that causes itch and hives that can be debilitating for young children, es...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.